

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

cyclin A (H-432)

RRID:AB_631329

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-751, RRID:AB_631329

Antibody Information

URL: http://antibodyregistry.org/AB_631329

Proper Citation: Santa Cruz Biotechnology Cat# sc-751, RRID:AB_631329

Target Antigen: cyclin A (H-432)

Host Organism: rabbit

Clonality: polyclonal

Comments: Discontinued: 2016; validation status unknown check with seller; recommendations: Western Blot; ELISA; Functional Assay; Immunofluorescence; Immunoprecipitation; Immunocytochemistry; Immunohistochemistry; WB, IP, IF, IHC(P), ELISA

Antibody Name: cyclin A (H-432)

Description: This polyclonal targets cyclin A (H-432)

Target Organism: Human, Rat, Mouse

Antibody ID: AB_631329

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-751

Record Creation Time: 20250819T223814+0000

Record Last Update: 20250820T024931+0000

Ratings and Alerts

No rating or validation information has been found for cyclin A (H-432).

Warning: Discontinued: 2016

Discontinued: 2016; validation status unknown check with seller; recommendations: Western Blot; ELISA; Functional Assay; Immunofluorescence; Immunoprecipitation; Immunocytochemistry; Immunohistochemistry; WB, IP, IF, IHC(P), ELISA

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Morshneva A, et al. (2025) An in vitro tumor recurrence model based on platinum-resistant colon cancer cells as a research tool for studying cancer cell dormancy. PloS one, 20(10), e0333671.

Huang X, et al. (2025) CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma. bioRxiv : the preprint server for biology.

Audrey A, et al. (2024) RAD52-dependent mitotic DNA synthesis is required for genome stability in Cyclin E1-overexpressing cells. Cell reports, 43(4), 114116.

Ling H, et al. (2024) HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression. NAR cancer, 6(2), zcae018.

Saxena S, et al. (2024) Unprocessed genomic uracil as a source of DNA replication stress in cancer cells. Molecular cell, 84(11), 2036.

Ramadan WS, et al. (2024) Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives. iScience, 27(1), 108659.

Ling H, et al. (2023) HDAC10 blockade upregulates SPARC expression thereby repressing melanoma cell growth and BRAF inhibitor resistance. bioRxiv : the preprint server for biology.

Arora M, et al. (2023) Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. Cell, 186(12), 2628.

Martinez MJ, et al. (2023) Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer. iScience, 26(9), 107681.

Ouyang H, et al. (2023) p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP. Cell reports, 42(12), 113486.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Wang YC, et al. (2023) Arginine shortage induces replication stress and confers genotoxic resistance by inhibiting histone H4 translation and promoting PCNA ubiquitination. *Cell reports*, 42(4), 112296.

Nakagawa T, et al. (2022) SPT16 ubiquitylation by DCAF14-CRL4 regulates FACT binding to histones. *Cell reports*, 38(12), 110541.

Nicolas AM, et al. (2022) Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. *Cancer cell*, 40(2), 168.

Guo Y, et al. (2022) Histone H2A ubiquitination resulting from Brap loss of function connects multiple aging hallmarks and accelerates neurodegeneration. *iScience*, 25(7), 104519.

Liu JCY, et al. (2021) Mechanism and function of DNA replication-independent DNA-protein crosslink repair via the SUMO-RNF4 pathway. *The EMBO journal*, 40(18), e107413.

Enrico TP, et al. (2021) Cyclin F drives proliferation through SCF-dependent degradation of the retinoblastoma-like tumor suppressor p130/RBL2. *eLife*, 10.

Ruggiano A, et al. (2021) The protease SPRTN and SUMOylation coordinate DNA-protein crosslink repair to prevent genome instability. *Cell reports*, 37(10), 110080.

Lee KY, et al. (2021) Chk1 promotes non-homologous end joining in G1 through direct phosphorylation of ASF1A. *Cell reports*, 34(4), 108680.

Zaher DM, et al. (2021) A Novel Benzopyrane Derivative Targeting Cancer Cell Metabolic and Survival Pathways. *Cancers*, 13(11).